Genetic aberrations and survival in plasma cell leukemia

R. E. Tiedemann, N. Gonzalez-Paz, R. A. Kyle, R. Santana-Davila, T. Price-Troska, S. A. Van Wier, W. J. Chng, R. P. Ketterling, Morie Gertz, K. Henderson, P. R. Greipp, Angela Dispenzieri, Martha Lacy, S Vincent Rajkumar, Peter Leif Bergsagel, Alexander Keith Stewart, Rafael Fonseca

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma (MM). We report here the genetic aberrations and survival of 80 patients with pPCL or sPCL and make comparisons with 439 cases of MM. pPCL presents a decade earlier than sPCL (54.7 vs 65.3 years) and is associated with longer median overall survival (11.1 vs 1.3 months; P < 0.001). 14q32 (IgH) translocations are highly prevalent in both sPCL and pPCL (82-87%); in pPCL IgH translocations almost exclusively involve 11q13 (CCND1), supporting a central etiological role, while in sPCL multiple partner oncogenes are involved, including 11q13, 4p16 (FGFR3/MMSET) and 16q23 (MAF), recapitulating MM. Both show ubiquitous inactivation of TP53 (pPCL 56%; sPCL 83%) by coding mutation or 17p13 deletion; complemented by p14ARF epigenetic silencing in sPCL (29%). Both show frequent N-RAS or K-RAS mutation. Poor survival in pPCL was predicted by MYC translocation (P = 0.006). Survival in sPCL was consistently short. Overall pPCL and sPCL are different disorders with distinct natural histories, genetics and survival.

Original languageEnglish (US)
Pages (from-to)1044-1052
Number of pages9
JournalLeukemia
Volume22
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Plasma Cell Leukemia
Multiple Myeloma
Survival
Tumor Suppressor Protein p14ARF
Mutation
Sexual Partners
Hematologic Neoplasms
Natural History
Oncogenes
Epigenomics

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Tiedemann, R. E., Gonzalez-Paz, N., Kyle, R. A., Santana-Davila, R., Price-Troska, T., Van Wier, S. A., ... Fonseca, R. (2008). Genetic aberrations and survival in plasma cell leukemia. Leukemia, 22(5), 1044-1052. https://doi.org/10.1038/leu.2008.4

Genetic aberrations and survival in plasma cell leukemia. / Tiedemann, R. E.; Gonzalez-Paz, N.; Kyle, R. A.; Santana-Davila, R.; Price-Troska, T.; Van Wier, S. A.; Chng, W. J.; Ketterling, R. P.; Gertz, Morie; Henderson, K.; Greipp, P. R.; Dispenzieri, Angela; Lacy, Martha; Rajkumar, S Vincent; Bergsagel, Peter Leif; Stewart, Alexander Keith; Fonseca, Rafael.

In: Leukemia, Vol. 22, No. 5, 05.2008, p. 1044-1052.

Research output: Contribution to journalArticle

Tiedemann, RE, Gonzalez-Paz, N, Kyle, RA, Santana-Davila, R, Price-Troska, T, Van Wier, SA, Chng, WJ, Ketterling, RP, Gertz, M, Henderson, K, Greipp, PR, Dispenzieri, A, Lacy, M, Rajkumar, SV, Bergsagel, PL, Stewart, AK & Fonseca, R 2008, 'Genetic aberrations and survival in plasma cell leukemia', Leukemia, vol. 22, no. 5, pp. 1044-1052. https://doi.org/10.1038/leu.2008.4
Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008 May;22(5):1044-1052. https://doi.org/10.1038/leu.2008.4
Tiedemann, R. E. ; Gonzalez-Paz, N. ; Kyle, R. A. ; Santana-Davila, R. ; Price-Troska, T. ; Van Wier, S. A. ; Chng, W. J. ; Ketterling, R. P. ; Gertz, Morie ; Henderson, K. ; Greipp, P. R. ; Dispenzieri, Angela ; Lacy, Martha ; Rajkumar, S Vincent ; Bergsagel, Peter Leif ; Stewart, Alexander Keith ; Fonseca, Rafael. / Genetic aberrations and survival in plasma cell leukemia. In: Leukemia. 2008 ; Vol. 22, No. 5. pp. 1044-1052.
@article{9efc24a7ee94433cbf53cbbe5ec1a0f9,
title = "Genetic aberrations and survival in plasma cell leukemia",
abstract = "Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma (MM). We report here the genetic aberrations and survival of 80 patients with pPCL or sPCL and make comparisons with 439 cases of MM. pPCL presents a decade earlier than sPCL (54.7 vs 65.3 years) and is associated with longer median overall survival (11.1 vs 1.3 months; P < 0.001). 14q32 (IgH) translocations are highly prevalent in both sPCL and pPCL (82-87{\%}); in pPCL IgH translocations almost exclusively involve 11q13 (CCND1), supporting a central etiological role, while in sPCL multiple partner oncogenes are involved, including 11q13, 4p16 (FGFR3/MMSET) and 16q23 (MAF), recapitulating MM. Both show ubiquitous inactivation of TP53 (pPCL 56{\%}; sPCL 83{\%}) by coding mutation or 17p13 deletion; complemented by p14ARF epigenetic silencing in sPCL (29{\%}). Both show frequent N-RAS or K-RAS mutation. Poor survival in pPCL was predicted by MYC translocation (P = 0.006). Survival in sPCL was consistently short. Overall pPCL and sPCL are different disorders with distinct natural histories, genetics and survival.",
author = "Tiedemann, {R. E.} and N. Gonzalez-Paz and Kyle, {R. A.} and R. Santana-Davila and T. Price-Troska and {Van Wier}, {S. A.} and Chng, {W. J.} and Ketterling, {R. P.} and Morie Gertz and K. Henderson and Greipp, {P. R.} and Angela Dispenzieri and Martha Lacy and Rajkumar, {S Vincent} and Bergsagel, {Peter Leif} and Stewart, {Alexander Keith} and Rafael Fonseca",
year = "2008",
month = "5",
doi = "10.1038/leu.2008.4",
language = "English (US)",
volume = "22",
pages = "1044--1052",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Genetic aberrations and survival in plasma cell leukemia

AU - Tiedemann, R. E.

AU - Gonzalez-Paz, N.

AU - Kyle, R. A.

AU - Santana-Davila, R.

AU - Price-Troska, T.

AU - Van Wier, S. A.

AU - Chng, W. J.

AU - Ketterling, R. P.

AU - Gertz, Morie

AU - Henderson, K.

AU - Greipp, P. R.

AU - Dispenzieri, Angela

AU - Lacy, Martha

AU - Rajkumar, S Vincent

AU - Bergsagel, Peter Leif

AU - Stewart, Alexander Keith

AU - Fonseca, Rafael

PY - 2008/5

Y1 - 2008/5

N2 - Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma (MM). We report here the genetic aberrations and survival of 80 patients with pPCL or sPCL and make comparisons with 439 cases of MM. pPCL presents a decade earlier than sPCL (54.7 vs 65.3 years) and is associated with longer median overall survival (11.1 vs 1.3 months; P < 0.001). 14q32 (IgH) translocations are highly prevalent in both sPCL and pPCL (82-87%); in pPCL IgH translocations almost exclusively involve 11q13 (CCND1), supporting a central etiological role, while in sPCL multiple partner oncogenes are involved, including 11q13, 4p16 (FGFR3/MMSET) and 16q23 (MAF), recapitulating MM. Both show ubiquitous inactivation of TP53 (pPCL 56%; sPCL 83%) by coding mutation or 17p13 deletion; complemented by p14ARF epigenetic silencing in sPCL (29%). Both show frequent N-RAS or K-RAS mutation. Poor survival in pPCL was predicted by MYC translocation (P = 0.006). Survival in sPCL was consistently short. Overall pPCL and sPCL are different disorders with distinct natural histories, genetics and survival.

AB - Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma (MM). We report here the genetic aberrations and survival of 80 patients with pPCL or sPCL and make comparisons with 439 cases of MM. pPCL presents a decade earlier than sPCL (54.7 vs 65.3 years) and is associated with longer median overall survival (11.1 vs 1.3 months; P < 0.001). 14q32 (IgH) translocations are highly prevalent in both sPCL and pPCL (82-87%); in pPCL IgH translocations almost exclusively involve 11q13 (CCND1), supporting a central etiological role, while in sPCL multiple partner oncogenes are involved, including 11q13, 4p16 (FGFR3/MMSET) and 16q23 (MAF), recapitulating MM. Both show ubiquitous inactivation of TP53 (pPCL 56%; sPCL 83%) by coding mutation or 17p13 deletion; complemented by p14ARF epigenetic silencing in sPCL (29%). Both show frequent N-RAS or K-RAS mutation. Poor survival in pPCL was predicted by MYC translocation (P = 0.006). Survival in sPCL was consistently short. Overall pPCL and sPCL are different disorders with distinct natural histories, genetics and survival.

UR - http://www.scopus.com/inward/record.url?scp=43749090639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749090639&partnerID=8YFLogxK

U2 - 10.1038/leu.2008.4

DO - 10.1038/leu.2008.4

M3 - Article

C2 - 18216867

AN - SCOPUS:43749090639

VL - 22

SP - 1044

EP - 1052

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -